I'm of the opinion that they have known for quite some time that the only way to meet the demand, be profitable, and make it affordable to patients and RA's was to have a highly automated way of making the vaccine. Without that, it would be a bespoke treatment that only the wealthy could afford. By meeting that challenge, I believe they are putting themselves at a very competitive advantage. I think they are going to give the CAR-T and mRNA vaccines a run for their money in terms of pricing, efficacy and safety once the EDEN units are in place.
Market Data 
Markets 
AI
